Adverse clinical outcome in Hodgkin's disease is associated with loss of retinoblastoma protein expression, high Ki67 proliferation index, and absence of Epstein-Barr Virus-latent membrane protein 1 expression

Blood

Volumn 90, Issue 6, 1997, Pages 2429-2436

  Morente, Manuel M ^a   Piris, Miguel A ^b   Abraira, Victor ^b   Acevedo, Agustin ^b   Aguilera, Beatriz ^b   Bellas, Carmen ^b   Fraga, Máximo ^b   Garcia Del Moral, Raimundo ^b   Gomez Marcos, Francisco ^b   Menarguez, Javier ^b   Oliva, Horacio ^b   Sanchez Beato, Margarita ^b   Montalban, Carlos ^b  

^a HOSPITAL UNIVERSITARIO DE GUADALAJARA   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD15 ANTIGEN; KI 67 ANTIGEN; MEMBRANE PROTEIN; PROTEIN P53; RETINOBLASTOMA PROTEIN; VIRUS PROTEIN;

ADULT; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HODGKIN DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; ONCOGENE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REMISSION; RETINOBLASTOMA; TUMOR SUPPRESSOR GENE;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD15; CELL DIVISION; CHILD; CHILD, PRESCHOOL; FEMALE; HODGKIN DISEASE; HUMANS; KI-67 ANTIGEN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; REGRESSION ANALYSIS; RETINOBLASTOMA PROTEIN; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53; VIRAL MATRIX PROTEINS;

EID: 0030801898     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Gobbi PG, Cavalli C, Gendarini A, Crema A, Ricevuti G, Federico M, Di-Prisco U, Ascari E: Reevaluation of prognostic significance of symptoms in Hodgkin's disease. Cancer 56:2874, 1985
2. Straus DJ, Gaynor JJ, Myers J, Merke DP, Caravelli J, Chapman D, Yahalom J, Clarkson BD: Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy. J Clin Oncol 8:1173, 1990
3. Mauch P, Larson D, Osteen R, Silver B, Yeap B, Canellos G, Weinstein H, Rosenthal D, Pinkus G, Jochelson M, Coleman CN, Hellman S: Prognostic factors for positive surgical staging in patients with Hodgkin's disease. J Clin Oncol 8:257, 1990
4. Specht L: Tumour burder as the main indicator of prognosis in Hodgkin's disease. Eur J Cancer 28:1982, 1992
5. Inghirami G, Frizzera G: Role of the Bcl-2 oncogene in Hodgkin's disease. Am J Clin Pathol 101:681, 1994
6. Corbally N, Grogan L, Keane MM, Devaney DM, Dervan PA, Carney DN: Bcl-2 rearrangement in Hodgkin's disease and reactive lymph nodes. Am J Clin Pathol 101:756, 1994
7. Imamura J, Miyoshi I, Koeffler HP: p53 in haematologic malignancies. Blood 84:2412, 1994
8. Sanchez-Beato M, Martinez-Montero JC, Doussis-Anagnostopoulou IA, Gatter KC, García FJ, Garcia JF, LLoret E, Piris MA: Anomalous retinoblastoma protein expression in Sternberg-Reed cells in Hodgkin's disease: A comparative study with p53 and Ki67 expression. Br J Cancer 74:1056, 1996
9. Pasman PC, Tiebosch A, Erdkamp FL, Vrints LW, Breed WP, Schouten HC: P53 as a marker of the malignant cell in Hodgkin's disease. Ann Oncol 5:S89, 1994 (suppl 1)
10. Xerri L, Bouabdallah R, Carmelo J, Hassoun J: Expression of p53 gene in Hodgkin's disease: Disotiation between immunohistochemistry and clinicopathological data. Hum Pathol 25:449, 1994
11. WAF1/CIP1, wild-type p53-induced proteins, are regularly expressed by Sternberg-Reed cells in Hodgkin's disease. J Pathol 180:58, 1996
12. Khan G, Coates PJ: The role of Epstein-Barr virus in the pathogenesis of Hodgkin's disease. J Pathol 174:141, 1994
13. Diehl V, Tesch H: Hodgkin's disease: Environmental or genetic? N Engl J Med 332:461, 1995
14. Hermine O, Haioun C, Lepage E, d'Agay MF, Briere J, Levignac C, Fillet G, Salles G, Merolleau JP, Diebold J, Reyes F, Gaulard P: Prognostic significance of bcl-2 protein expression in agressive non-Hodgkin's lymphoma. Blood 87:265, 1996
15. Piris MA, Pezzella F, Martinez-Montero JC, Orradre JL, Villuendas R, Sanchez-Beato M, Cuena R, Cruz MA, Martinez B, Garrido MC, Gatter K, Aiello A, Delia D, Giardini R, Rilke F: p53 and bcl2 expression in high grade B-cell lymphomas. Correlation with survival time. Br J Cancer 69:337, 1994
16. Piris MA, Villuendas R, Martinez JC, Sanchez-Beato M, Orradre JL, Mateo MS, Martinez P: p53 expression in non-Hodgkin's lymphomas: A marker of p53 inactivation? Leuk Lymphoma 17:35, 1995
17. Louie DC, Offit K, Jaslow R, Parsa NZ, Murty VVVS, Schluger A, Chaganti RSK: p53 overexpression as a marker of poor prognosis in mantle cell lymphomas with t(11;14)(q13;q32). Blood 86:2892, 1995
18. Cance WG, Brennan MF, Dudas ME, Huang CM, Cordon-Cardo C: Altered expression of the retinoblastoma gene product in human sarcomas. N Engl J Med 323:1457, 1990
19. D'Amore F, Johansen P, Houmand A, Weisenburger DD, Mortensen LS: Epstein-Barr Virus genome in non-Hodgkin's lymphomas occurring in immunocompetent patients: Highest prevalence in nonlymphoblastic T-cell lymphoma and correlation with a poor prognosis. Blood 87:1045, 1996
20. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H: Cell cycle analysis of a cell proliferation-associated human nuclear antigen denned by the monoclonal antibody Ki-67. J Immunol 133:1710, 1984
21. Grogan TM, Lippman SM, Spier CM, Slymen DJ, Rybski JA, Rangel CS, Richter LC, Miller TP: Independent prognostic significance of a nuclear proliferation antigen in diffuse large cell lymphomas as determined by the monoclonal antibody Ki67. Blood 71:1157, 1988
22. Miller TP, Grogan TM, Dahlberg S, Spier CM, Braziel RM, Banks PM, Foucar K, Kjeldsberg CR, Levy N, Nathwani BN, Schnitzer B, Tubbs RR, Gaynor ER, Fisher RI: Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: A prospective Southwest Oncology Group Trial. Blood 83:1460, 1994
23. Lukes RJ, Butler JJ: The pathology and nomenclature of Hodgkin's disease. Cancer Res 26:1063, 1996
24. Battifora H: Assessment of antigen damage in immunohistochemistry. The vimentin internal control. Am J Clin Pathol 96:669, 1991
25. McKee PH, Hobbs C, Hall PA: Antigen retrieval by microwave irradiation lowers immunohistological detection thresholds. Histopathology 23:377, 1993
26. Claviez A, Tiemann M, Peters J, Kreipe H, Schneppenheim R, Parwaresch R: The impact of EBV, proliferation rate and bcl-2 expression in Hodgkin's disease in childhood. Ann Hematol 68:6, 1994
27. Martinez-Montero JC, Piris MA, Sanchez-Beato M, Villuendas R, Orradre JL, Algara P, Sanchez-Verde L, Martinez P: Retinoblastoma (Rb) gene product expression in lymphomas. Correlation with ki67 growth fraction. J Pathol 169:405, 1993
28. Cattoretti G, Becker MHG, Key G, Duchrow M, Schlüter C, Galle J, Gerdes J: Monoclonal antibodies against recombinant parts of the Ki67 antigen (MIB1 and MIB3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 168:357, 1992
29. Cox DR: Regression models and life tables. J Stat Soc (B) 34:187, 1972
30. Abraira V, Pérez-de-Vargas A: Métodos Multivariantes en Bioestadística. Madrid, Centro de Estudios Ramón Areces, 1996
31. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457, 1958
32. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG: Design and analysis of randomized clinical trials requiring prolonged observations of each patients: II. Analysis and examples. Br J Cancer 35:1, 1977
33. Cox DR, Oakes D: Analysis of Survival Data. London, UK, Chapman & Hall, 1984
34. Beisley DA: Conditioning diagnostics: Collinearity and weak data in regression. New York, NY, Wiley, 1991
35. Abraira V, Zaplana J: Un paquete de procesamientos estadísticos. Conferencia Iberoamericana de Bioingenieria (October 1984). Madrid, Spain, 1984, p 101
36. Gerdes J: Ki-67 and other proliferation markers useful for immunohistological diagnostic and prognostic evaluation in human malignancies. Semin Cancer Biol 1:199, 1990
37. Brown DC, Gatter KC: Monoclonal antobody Ki-67: Its use in histopathology. Histopathology 17:489, 1990
38. Mateo MS, Sanchez-Beato M, Martinez JC, Orfao A, Orradre JL, Piris MA: P53, RB and BCL-2 expression along the cell cycle. A study in PHA-stimulated lymphocytes and microwave irradiated lymphoid tissue sections. J Clin Pathol 48:151, 1995
39. Schouten HC, Sanger WG, Duggan M, Weisenburger DD, MacLennan KA, Armitage JO: Chromosomal abnormalities in Hodgkin's disease. Blood 73:2149, 1989
40. Tilly H, Bastard C, Delastre T, Duval C, Bizet M, Lenormand B, Dauce JP, Monconduit M, Piguet H: Cytogenetic studies in untreated Hodgkin's disease. Blood 77:1298, 1991
41. Xu HJ, Xu SX, Cagle PT, Moore GE, Benedict WF: Absence of retinoblastoma protein expression in primary non-small cell lung carcinomas. Cancer Res 51:2735, 1991
42. Cordón-Cardo C, Wartinger D, Petrylak D, Dalbagni G, Fair WR, Fuks Z, Reuter VE: Altered expression of the retinoblastoma gene product as indicator in bladder cancer. J Natl Cancer Inst 84:125, 1992
43. Kornblau SM, Chen N, Del Giglio A, O'Brien S, Deisseroth B: Retinoblastoma protein expression is frecuently altered in chronic lymphocytic leukemia. Cancer Res 54:242, 1994
44. Rickinson AB, Murray RJ, Brooks J, Griffin H, Moss DJ, Masucci MG: T-cell recognition of Epstein-Barr virus associated lymphomas. Cancer Surv 13:53, 1992
45. Knecht H, Bachmann E, Joske DJL, Sahli R, Emery-Goodman A, Casanova JL, Zilic M, Bachmann F, Odermatt BF: Molecular analysis of LMP (Latent membrane protein) oncogene in Hodgkin's disease. Leukemia 7:580, 1993
46. Santon A, Manzanal AI, Campo E, Bellas C: Deletions in the Epstein-Barr virus latent membrane protein-1 oncogen in Hodgkin's disease. J Clin Pathol: Mol Pathol 48:M184, 1995
47. Triveldi P, Hu LF, Christensson B, Masucci MG, Klein G, Winberg G: Epstein-Barr virus (EBV)-encoded membrane protein LMP1 from a nasopharingeal carcinoma is non-immunogenic in murine model system, in contrast to a B cell-derived homologue. Eur J Cancer 30:84, 1994
48. Knecht H, Bachmann E, Brousset P, Sandvej K, Nadal D, Bachmann F, Odermatt BF, Delsol G, Pallesen G: Deletions within the LMP-1 oncogen of Epstein-Barr virus are clustered in Hodgkin's disease and identical to those observed in nasophringeal carcinoma. Blood 82:2937, 1993
49. Sandvej K, Peh SC, Andresen BS, Pallesen G: Identification of potential hot spots in the carboxy-terminal part of the Epstein-Barr virus (EBV) BNLF-1 gene in both malignant and benign EBV-associated diseases: High frequency of a 30-bp delection in Malaysian and Danish peripheral T-cell lymphomas. Blood 84:4053, 1994
50. Fellbaum C, Hansmann ML, Niedemeyer H, Kraus I, Alavaikko MJ, Blanco G, Aine R, Busch R, Putz B, Fischer R, Höfler H: Influence of Epstein-Barr virus genomes on patient survival in Hodgkin's disease. J Clin Pathol 98:319, 1992